HC
CORT icon

Hurley Capital’s Corcept Therapeutics CORT Stock Holding History

Hurley Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.03K Hold
100
– – ﹤0.01% 482
2025
Q4 		$3.48K Hold
100
– – ﹤0.01% 476
2025
Q3 		$8.31K Buy
+100
New +$7.24K ﹤0.01% 383

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Hurley Capital's CORT Position: Q1 2026 in Review

Hurley Capital held its Corcept Therapeutics (CORT) position steady in Q1 2026 at 100 shares worth $4.03K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

Hurley Capital first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.31K in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Hurley Capital held 100 shares of Corcept Therapeutics worth $4.03K as of Q1 2026.
  • Hurley Capital left its Corcept Therapeutics share count unchanged in Q1 2026.
  • Corcept Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #482 holding.
  • Hurley Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Hurley Capital's Corcept Therapeutics position peaked at $8.31K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.